Also found in: Wikipedia.
AMGENApplied Molecular Genetics (original meaning)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Amgen said the acquisition of Otezla offers a unique opportunity to provide patients an oral therapy for psoriasis and psoriatic arthritis that fits within the company's portfolio and complements its Enbrel and Amgevita brands.
"It has been our longstanding belief all of Amgen's asserted US PCSK9 patent claims are invalid, and we are pleased today's decision reaffirms this," said Sanofi Executive Vice President & General Counsel Karen Linehan.
'Today's results with ABP 798 demonstrate another positive development from Amgen's robust pipeline of biosimilar medicines and we look forward to working with regulatory agencies to bring this treatment to patients,' said David M.
Amgen affiliates Immunex Corporation and Amgen Manufacturing, Limited, along with the owner and licensor of the two patents, Hoffmann-La Roche Inc., brought the patent infringement action in Federal Court against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (together, Sandoz).
Reportedly, the recommended public cash offer by Amgen Inc to the shareholders of Nuevolution to tender all their shares in Nuevolution to Amgen was declared unconditional and was completed by Amgen on 8 July 2019.
Biopharmaceutical company Nuevolution AB (STO:NUE) announced on Wednesday that its board of directors has unanimously recommended that shareholders accept the public offer from Amgen Inc of SEK32.50 in cash per share.
"Since its inception in 2002, Amgen Rhode Island has evolved to a multi-product manufacturing facility, which is a testament to our focus on innovation, technology and great staff," said Tia Bush, vice president of Operations at Amgen Rhode Island.
Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of Epogen (epoetin alfa).
The collaboration will combine Immatics' world-leading XPRESIDENT target discovery and T-cell receptor (TCR) capabilities with Amgen's validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
Amgen's Baa1 rating reflects its good competitive position as the largest stand-alone biotechnology company based on revenue and its strong profit margins.
Onyx had spurned an earlier bid of $120 a share by Amgen and had assigned Centerview Partners the task of finding a suitable bidder.